Migraine Without Aura
88
9
10
53
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Research Maturity
53 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.8%
6 terminated out of 88 trials
89.8%
+3.3% vs benchmark
19%
17 trials in Phase 3/4
17%
9 of 53 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 53 completed trials
Clinical Trials (88)
Trial Designs for Evaluating Migraine Treatment
Mind Body Balance for Pediatric Migraine
Responding With Evidence and Access for Childhood Headaches
ACT Therapy for HF Migraine
App-Based Migraine Treatment: The Health enSuite Study
Ditan Acute tReatments: Effectiveness and Tolerability (DART)
Gepant treAtments: EffectIveNess and tolERability (GAINER)
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)
Myotensive Extraocular Muscle Techniques Added to Manual Therapy for Migraine Without Aura
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Understanding the Pathophysiology of Migraine Pain
Migraine With and Without Aura Characteristics and Response to Remote Electrical Neuromodulation (REN) Treatment
Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura
Healthy Living Partnerships for Veterans With Migraine
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine
Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification